FAQ on CNS Pharmaceuticals Inc.'s Participation in the Webull Financial Biotech/MedTech Webinar Series

What is CNS Pharmaceuticals Inc. presenting at the Webull Financial Webinar?

CNS Pharmaceuticals Inc. will present its pipeline of anti-cancer drug candidates, including TPI 287, at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.

When is the Webull Financial Biotech/MedTech Webinar Series taking place?

The webinar is scheduled to take place virtually from August 19 to August 21, 2025.

What is TPI 287 and what is its significance?

TPI 287 is an abeotaxane developed by CNS Pharmaceuticals that stabilizes microtubules, inhibits cell division, and has shown potential to cross the blood-brain barrier to treat CNS tumors, with an excellent safety profile and high tolerability among patients.

Where can I find more information about CNS Pharmaceuticals Inc.?

More information about CNS Pharmaceuticals Inc. is available in the company’s newsroom at https://ibn.fm/CNSP.

What types of cancers has TPI 287 been tested for?

TPI 287 has been tested in clinical trials for recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain.

How can I view the full press release about CNS Pharmaceuticals Inc.’s webinar presentation?

The full press release can be viewed at https://ibn.fm/EOCy9.

What is the focus of CNS Pharmaceuticals Inc.?

CNS Pharmaceuticals Inc. focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system.

Who can benefit from attending the Webull Financial Biotech/MedTech Webinar Series?

Investors, healthcare professionals, and anyone interested in the latest developments in biotech and medtech, especially in cancer treatment, can benefit from attending the webinar.